Discover the benefits of population genomics
Helix's end-to-end platform enables health systems, life sciences companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical care
Learn moreAn end-to-end population genomics platform
From recruitment support to Exome+® sequencing to return of results, we enable you to bring the power of genomics to your communities.
A panel-grade clinical exome
The Exome+ assay delivers the benefits of a targeted panel, the breadth of a microarray, and the completeness of an exome all from one assay
Genomics research platform
The Helix platform, with its dedicated clinical and research teams, supports you in delivering actionable genetic insights and conducting large-scale genetic analyses
Sequence once, query often
Helix sequences and securely stores Exome+ data on behalf of each participant enabling flexible and on-demand access to genomic data, with the proper consent
Advancing population genomics
COVID-19 Efforts
COVID-19 testing
Helix is now offering an end-to-end COVID-19 test system along with viral sequencing, surveillance, and research
Learn more
The Healthy Nevada Project
Real-world impact
Learn how we’re working with Renown Health to improve health outcomes and advance genomics research
Case study
The Helix Laboratory Platform
FDA Authorized Whole Exome Sequencing
A landmark authorization defines a path forward for test development
Learn more
COVID-19 testing
We've launched a sensitive, scalable, end-to-end COVID-19 test system to meet the needs of health systems, employers, governments, and other organizations across the country.
Our test system includes a non-invasive collection kit, processing of samples in our CLIA-certified, CAP-accredited high-complexity laboratory in San Diego, next-day turnaround time, and return of results to the ordering healthcare professional, the tested individual, and public health agencies, as necessary. We have also partnered with Illumina to launch a viral surveillance program.
Viral surveillance sequencing program
Helix and Illumina, with support from the CDC, are collaborating to augment national surveillance infrastructure in the US to track the emergence and prevalence of novel variants of SARS-CoV-2. Sequences are deposited regularly to GISAID and Genbank by the CDC. All B.1.1.7 variants are also reported to relevant public health departments for contact tracing efforts.
The Exome+® Assay
The Exome+ assay provides a clinical exome enhanced by ~300,000 informative non-coding regions. Due to its custom design and proprietary bioinformatics solutions, it enables both clinical return of results and supports research applications with: >99.5% call rate at ≥20x depth for clinically relevant regions, accurate detection of >100 CYP2D6 star alleles, array-equivalent genome-wide imputation of tens of millions of high-confidence SNPs for discovery and polygenic risk scores, and coverage of the entire mitochondrial genome.
Learn more.
Privacy is one of our top priorities.
We won’t share data without a participant’s permission. We pledge to uphold the highest standards of bioethics and maintain rigorous policies and procedures to keep data safe and secure.
Partner with us
Helix provides the infrastructure and services to help you carry out population-scale genomic screening and research initiatives, including one of the world's largest CLIA / CAP next-generation sequencing labs. Together, we can drive earlier identification of at-risk individuals and accelerate innovative research efforts.
Interested in our personal DNA tests?
Explore our suite of DNA tests to help you assess your genetic risk for certain health conditions, understand more about your genetic ancestry, and discover how your DNA may influence your many traits.
*Note: Due to disruptions related to COVID-19, results may be delayed.
Learn more*Panel-grade: defined as a ~100% call rate across every base within clinically relevant panels (offering equivalent or superior quality to clinical panels in the market).